Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy
- PMID: 10534512
- DOI: 10.1093/ndt/14.11.2680
Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy
Abstract
Background: Iron balance is critical for adequate erythropoiesis and there remains much debate concerning the optimal timing and dosage of iron therapy for haemodialysis patients receiving recombinant human erythropoietin therapy.
Methods: In this study, we examined the influence of baseline ferritin level and intravenous infusion of 100 mg ferric saccharate on the oxidative status of the patients on maintenance haemodialysis. The levels of antioxidant enzymes and lipid peroxides were determined in erythrocytes and plasma of 50 uraemic patients on haemodialysis. These patients were divided into groups 1, 2, and 3, based on their baseline serum ferritin levels of <300, 301-600, and >601 microg/l, respectively.
Results: We found that the mean superoxide dismutase (SOD) activities in the erythrocytes were similar in the three groups of patients and did not differ from those of the age-matched controls. On the other hand, all the haemodialysis patients showed significantly higher plasma SOD activity as compared to controls. After intravenous iron infusion, group 3 patients showed the largest decrease in plasma SOD activity. The plasma glutathione peroxidase (GSHPx) activities of the patients in all three groups and the erythrocyte GSHPx activities of the patients in the groups 2 and 3 were lower than those of the healthy controls. In all three groups of patients, no difference in GSHPx activity was found before and after intravenous iron infusion. On the other hand, we found that the average baseline levels of plasma lipid peroxides of all three groups of patients were significantly higher than that of the controls. The patients in group 3 with the highest serum ferritin levels showed the highest levels of plasma lipid peroxides. More importantly, we found that after iron infusion, the patients in all three groups, particularly those in group 3, showed significantly elevated levels of plasma lipid peroxides.
Conclusion: We demonstrated that increased oxidative stress in the blood circulation of the uraemic patients on haemodialysis is exacerbated by the elevated baseline serum ferritin levels and intravenous iron infusion. The resultant oxidative damage may contribute to the increased incidence of atherosclerosis in the patients with end-stage renal disease on long-term haemodialysis.
Similar articles
-
Effect of intravenous iron sucrose on oxidative stress in peritoneal dialysis patients.Ren Fail. 2007;29(7):849-54. doi: 10.1080/08860220701573566. Ren Fail. 2007. PMID: 17994454
-
Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients.Nephrol Dial Transplant. 2003 Feb;18(2):370-7. doi: 10.1093/ndt/18.2.370. Nephrol Dial Transplant. 2003. PMID: 12543894
-
Iron supplementation in haemodialysis--practical clinical guidelines.Nephrol Dial Transplant. 1998 Oct;13(10):2572-7. doi: 10.1093/ndt/13.10.2572. Nephrol Dial Transplant. 1998. PMID: 9794562 Clinical Trial.
-
Effect of intravenous iron supplementation on erythropoiesis in erythropoietin-treated premature infants.Pediatrics. 2001 Jan;107(1):78-85. doi: 10.1542/peds.107.1.78. Pediatrics. 2001. PMID: 11134438 Clinical Trial.
-
Potential risk for infection and atherosclerosis due to iron therapy.J Ren Nutr. 2005 Jan;15(1):105-10. doi: 10.1053/j.jrn.2004.09.018. J Ren Nutr. 2005. PMID: 15648017 Review.
Cited by
-
Utilization Patterns of IV Iron and Erythropoiesis Stimulating Agents in Anemic Chronic Kidney Disease Patients: A Multihospital Study.Anemia. 2012;2012:248430. doi: 10.1155/2012/248430. Epub 2012 Apr 19. Anemia. 2012. PMID: 22577528 Free PMC article.
-
The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale.BMC Nephrol. 2017 Apr 3;18(1):117. doi: 10.1186/s12882-017-0523-8. BMC Nephrol. 2017. PMID: 28372549 Free PMC article. Clinical Trial.
-
Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy.J Mol Med (Berl). 2006 May;84(5):349-64. doi: 10.1007/s00109-005-0029-x. Epub 2006 Apr 8. J Mol Med (Berl). 2006. PMID: 16604332 Free PMC article. Review.
-
Effects of carnitine on oxidative stress response to intravenous iron administration to patients with CKD: impact of haptoglobin phenotype.BMC Nephrol. 2015 Aug 13;16:135. doi: 10.1186/s12882-015-0119-0. BMC Nephrol. 2015. PMID: 26268514 Free PMC article. Clinical Trial.
-
Iron therapy for renal anemia: how much needed, how much harmful?Pediatr Nephrol. 2007 Apr;22(4):480-9. doi: 10.1007/s00467-006-0405-y. Epub 2007 Jan 6. Pediatr Nephrol. 2007. PMID: 17206511 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical